

Decision Letter

April 19, 2013

**Dr. David Grant
University of Toronto
Surgery
585 University Avenue
Toronto, Ontario
M5G 2N2**

Dear Dr. Grant

RE: fgl2/FGL2 and Heart Allotransplantation

The Heart and Stroke Foundation of Canada (the Foundation) is pleased to inform you that your 2013/14 Grant-in-Aid application has been successful. Details on the approved annual budget, as well as the key terms and conditions associated with this award, are outlined below.

GIA Award Agreement

Please read this letter carefully and indicate your acceptance of the award below. By indicating that you accept this award, you will generate a PDF copy of a GIA Award Agreement that must be signed by you and the grantee institution. Funding of your project is subject to you being in compliance with the terms and conditions of the GIA Award Agreement at all times.

Accounting

A new research account will be opened at your institution for this grant. All expenses should be submitted to Financial Services at your institution, which will reimburse you for the costs of your project. Any significant deviations from the budget submitted with your application should be brought to the attention of the Foundation prior to the disbursement of funds.

The grantee institution must provide the Foundation with an annual financial report for your grant. If it is determined that the project is significantly under spent, the Foundation reserves the right to withhold funds from the following year's support.

Funding Conditions

This award is contingent on the ability of the Foundation to meet all of its financial requirements. If the Foundation determines that insufficient funds are available at any time, it reserves the right to decrease or discontinue funding.

Reports

The Principal Investigator is required to submit via CIRCULink three types of reports during and after the term of the grant: an annual progress report, a final report, and a close-out report. Failure to submit a satisfactory report (i.e. progress, final, and/or close-out) by the specified timeframe may result in termination of funding and/or subsequent grant applications not being accepted for funding consideration. CIRCULink will send a reminder notification to the Principal Investigator to submit a Progress, Final, or Close-out Report well before the due date of the report.

Patents

The Foundation requests that the Principal Investigator review the Foundation Patent Rights Policy as set out in the Foundation's Grant-in-Aid Award (GIA) Management Guidelines. This document outlines the Foundation's rights and interests in any patent applications or patents approved that are the result of work completed under the research grant provided to you by the Foundation. It is the Foundation's intent to ensure that its donors' contributions are adequately reflected in any commercial venture and are invested in future research. If you have any questions or need specific clarification about a patent issue as it relates to your grant, please contact the designated Foundation research contact.

Other Sources of Funding

It is the responsibility of the Principal Investigator to inform the Foundation if additional funds are received from another agency to support the project named above. A letter detailing the additional funding must be forwarded to the designated Foundation research contact.

Acknowledgement

The Principal Investigator must acknowledge the support of the Foundation in all publications, presentations, and other communication related to the grant. In addition, a copy of publications must be submitted with the appropriate report (i.e. progress, final, close-out).

Research Communication

We would like to encourage you to help us communicate the importance of research to Foundation donors and to the general public. In this increasingly difficult economic climate, raising funds to support research is becoming progressively more difficult. More than ever, we need to let our donors and the public know that their donations are being used to support world class research. You are one of the best representatives to explain to the public the role of research in increasing heart health and reducing the burden of heart disease and stroke. To learn about the Foundation's volunteer activities please contact research@hsf.ca.

Best wishes for a successful year.

Sincerely,

**Peter Backx, DVM, PhD
Chair, Scientific Review Committee
Heart and Stroke Foundation**

Please find in the left hand menu of this screen a link to the HSF Grant-in-Aid (GIA) Award Agreement and the GIA Management Guidelines. The GIA Award Agreement must be reviewed and signed by both the Principal Investigator and an appropriate member at the Host Institution prior to accepting the award.

	2013/14	2013/14	2014/15	2014/15	2015/16	2015/16
	Requested	Final	Requested	Final	Requested	Final
Salary	\$52,800.00	\$52,800.00	\$52,800.00	\$52,800.00	\$52,800.00	\$52,800.00
Benefits	\$15,629.00	\$15,629.00	\$15,629.00	\$15,629.00	\$15,629.00	\$15,629.00
Equipment	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Experimental Animals	\$10,000.00	\$10,000.00	\$10,000.00	\$10,000.00	\$10,000.00	\$10,000.00
Materials and Supplies	\$21,000.00	\$21,000.00	\$21,000.00	\$21,000.00	\$21,000.00	\$21,000.00
Service Contract	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Subtotal	\$99,429.00	\$99,429.00	\$99,429.00	\$99,429.00	\$99,429.00	\$99,429.00

Total HSF Funding: \$298,287.00

Reviewed by committee: V

Percentile Ranking within Committee 93.88%

Encumbrances

Type	Details
Grant Agreement	Please confirm th...
Ethics	The Foundation re...
Ethics	The Foundation re...

Encumbrances

Type: Grant Agreement

Details:

Please confirm that the original signed copy of the Grant Agreement has been sent to the HSF office (Ottawa).

Encumbrances

Type: Ethics

Details:

The Foundation requires an “animal” ethics approval form that is valid beyond the start date of this award. If the form is not currently available, you may return to complete this requirement when it becomes available.

Encumbrances

Type: Ethics

Details:

The Foundation requires a “biosafety” ethics approval form that is valid beyond the start date of this award. If the form is not currently available, you may return to complete this requirement when it becomes available.

Encumbrances

Type:

Details:

Research Award Acceptance Form

Please complete and submit this form no later than 06/05/2013.

Grant Number: G-13-0002851

I accept the Foundation's offer of funding: Yes

I confirm as part of my acceptance:

I have read and agree to abide by all terms outlined in the agreement. ☒

I have attached a pdf copy of the GIA Award Agreement to this submission and I agree to forward the original to HSF offices. ☒

Confirm the name of the financial institution administering the grant. University Health Network

I acknowledge that the same/similar application has been submitted to the March competition at CIHR. ☐

Name of Principal Investigator: David Grant

Email of Principal Investigator: david.grant@uhn.ca

Date: 2013/04/23

Attachement Form - GIA Grant Agreement

Document Type	Required?	Document Description:	Date Attached
Attachment Form - GIA Grant Agreement	Yes	Signed GIA Grant ...	2013/04/23
Other	No	Biosafety Certifi...	2013/04/23

Attachment Details

Document Description: Signed GIA Grant Agreement

Attachment Details

Document Description: Biosafety Certificate

Attachment Details

Document Description:

Summary

Page	Last Updated
Award Acceptance	2013/04/23
Attach - Grant Agreement	2013/04/23
Summary	No Input Required

GRANT-IN-AID AWARD AGREEMENT (the "Agreement") 2013/2014



Principal Investigator: David Grant
Project Title: fgl2/FGL2 and Heart Allotransplantation
Funding period: 2013/14 to 2015/16
Project No.: G-13-0002851
Grantee Institution: University Health Network

1. Representations and Warranties of the Principal Investigator

In accepting a grant-in-aid from the Heart and Stroke Foundation of Canada ("HSFC" or the "Foundation"), the Principal Investigator, being the person in charge of the research being granted this award (the "Award"), makes the following representations and warranties:

- (a) that they have read and will comply with the terms of the Foundation's Grant-in-Aid Submission Guidelines (the "GIA Submission Guidelines") and Grant-in-Aid Award Management Guidelines (the "GIA Award Management Guidelines" and, together with the GIA Submission Guidelines, the "Guidelines");
- (b) that they have read and understand the following sections of the Guidelines:
 - (i) Section 8 – which outlines the right of the Foundation to participate in licensing and royalty profits from any discoveries made as a result of its support;
 - (ii) Section 9 – confirming that the Award does not cover indirect costs of research;
 - (iii) Section 10, that refers to the Foundation's Open Access to Research Outputs Policy; and
 - (iv) Section 14, governing personal financial gain to the applicant from the outcome of the research.
- (c) It has obtained the express written authorization of the grantee institution to conduct the research being funded under this Award in the form attached as Schedule A to this Agreement;
- (d) with respect to human and animal experimentation, as per Section 7 of the GIA Submission Guidelines:
 - (i) all investigations involving human subjects have been endorsed by the Principal Investigator's institution's ethics review board, or other clearly designated body, as ethical;

- (ii) all investigations involving human subjects conform to the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans and/or Human Pluripotent Stem Cell Research: Guidelines for CIHR-Funded Research;
- (iii) the research protocol and the care of animals for laboratory experimentation has been approved by the grantee institution's animal care committee and conforms to the Guiding Principles for Animal Experimentation as enunciated by the Canadian Council on Animal Care; and
- (iv) for all investigations involving human or animal subjects, the research has been reviewed and conforms with the guidelines outlined in Health Canada's Laboratory Biosafety Guidelines and that the research will not be undertaken until it has been accepted as meeting the requirements regarding biological and chemical hazards by such a review.

Under no circumstances will the Foundation fund research that involves human embryos that are created solely for research purposes or the derivation of stem cells from cloned human embryos that are created solely for research purposes.

- (e) all sources of funding, both active and applied for, and a complete list of all commercial research and development activities in which the Principal Investigator is engaged have been inputted into CIRCULink. This includes all private, public, and commercial research even if not related to the research pursuant to which this Award relates;
- (f) The Principal Investigator shall not, without prior written approval by the Foundation:
 - (i) use the name of the Foundation or any trademarks owned or licensed by the Foundation, including, without limitation, use in any press releases, advertisements, or publicity;
 - (ii) use the name of the Foundation in association with the raising of funds for a private or public company, partnership, or any other business arrangement; or
 - (iii) indicate in any manner that the Foundation is in "association" with or "partner" of "joint venturing" with any other person or agency.
- (g) funds received under this Agreement will only be spent on matters which are directly related to the research project pursuant to which this Award has been granted;
- (h) neither the Principal Investigator, nor any of its affiliates, have received funding from other sources which would constitute a duplication of the funding being awarded under this Agreement;
- (i) any matching funding for this project was correctly reported in the grant-in-aid application; and
- (j) If matching funding becomes available after the signing of this Agreement, that funding will be reported to the Foundation immediately using the appropriate section of CIRCULink.

For greater clarity, the Guidelines are incorporated by reference and form part of this Agreement.

2. Notice Requirements

The Principal Investigator must notify the Foundation immediately, in writing, if any of the following occur:

- (a) There is any significant deviation from the awarded budget;
- (b) If the Principal Investigator ceases to be an academic staff member at the original grantee institution during the term of this Award;
- (c) If the site where the research is being conducted changes; and
- (d) If the Principal Investigator cannot carry out the research or fulfill the purpose for which the Award was granted.

Notice must be given to the following address:

By email to: PeerReview@hsf.ca

OR

By Post to: Heart and Stroke Foundation of Canada
1402-222 Queen Street
Ottawa, Ontario K1P 5V9
Attention: Manager, Peer Review

3. Publication of Results

Results of the research must be made freely available to the public through appropriate scientific channels, and all publications will bear the statement: "This work was supported by a Grant-in-Aid from the Heart and Stroke Foundation of Canada." Notwithstanding the foregoing, discoveries that are patentable or protected as trade secrets need not be disclosed to the public if disclosure would result in loss of protection.

4. Reporting Requirements

The following are the reporting requirements of the Principal Investigator during and following termination of this Award:

- a) **Progress Report** – A satisfactory progress report must be filed with the Foundation on an annual basis by August 1st of the funding year. The report must be completed in the prescribed form and must be filed via CIRCULink. Failure to submit a satisfactory progress report in the prescribed form may result in termination of funding.

- b) Final Report - Following termination of the Award, a satisfactory final report must be filed with the Foundation on or before August 1st of the termination year. The report must be completed in the prescribed form and must be filed via CIRCULink.
- c) Close-Out Report – A satisfactory close-out-report must be filed with the Foundation before the first anniversary of the project completion date. The report must be completed in the prescribed form and must be filed via CIRCULink.

5. Limitations on Obligations

The Foundation reserves the right, in its sole discretion, to decrease or eliminate the funds awarded under this Agreement at any time. The granting of the Award is subject to the Foundation receiving a fully executed copy of this Agreement and the Grantee Institution Authorization Form attached as Schedule A.

6. Termination

The Foundation may terminate this Agreement at any time if:

- (a) in its sole discretion, there are insufficient funds available to support the Award; or
- (b) the Principal Investigator is in breach of any of its representations and warranties under this Agreement and such breach is not cured to the satisfaction of the Foundation within 30 days of the Principal Investigator being notified of the breach.

In the event the Agreement is terminated in accordance with this section, the Principal Investigator will return to HSFC the balance of any money awarded but not yet spent under this Agreement.

7. No Joint Venture or Partnership

Nothing in this Agreement shall be construed or interpreted to make HSFC and the Principal Investigator partners or joint venturers, or to make one an agent or representative of the other, or to afford any rights to any third party other than as expressly provided herein. None of HSFC or the Principal Investigator is authorized to bind the other to any other contract, agreement or understanding. HSFC is not responsible and specifically disclaims any liability for any claim, judgment, award for damages, settlement, negligence, or malpractice arising from any research or investigation related to the Award.

8. Assignment

This Agreement may not be assigned or transferred by the Principal Investigator without the prior written consent of HSFC, and any assignment without consent shall be null and void. This Agreement shall enure to the benefit of and be binding upon the respective permitted successors and assignees of the Principal Investigator.

9. Governing Law

This Agreement shall be governed by the laws of the Province of Ontario and the federal laws of Canada applicable therein.

By signing below, the Principal Investigator agrees to be bound by all of the foregoing terms. Funding is subject to the Principal Investigator being in compliance with the terms and conditions set out in this Agreement at all times. Failure to comply may result in the immediate termination of funding.

David Grant

Name of Principal Investigator

University Health Network

Name of Institution/Department Division



Signature of Principal Investigator

April 19, 2013

Date

Schedule A

Authorisation and Acknowledgement of Grantee Institution

Reference is made to the grant-in-aid Agreement signed by the Principal Investigator. All defined terms shall have the meaning given to them in the Agreement. The grantee institution is obligated to administer the Award in accordance with the governing regulations and policies of the Foundation or, where not specified, consistent with the policies and practices of the grantee institution. As a member of the Health Charities Coalition of Canada, the Foundation does not provide funding for indirect costs of research.

The grantee institution is obligated to ensure that the proper ethics reviews have been performed on the research project to which this Award pertains, and that these reviews are maintained and in good standing.

Assurance is given by the grantee institution that any human experimentation will be acceptable to the grantee institution on ethical grounds and that in the case of animal experimentation, the guiding principles enunciated by the Canadian Council on Animal Care's Guiding Principles for Animal Experimentation will be adhered to and that the proposed research will not be undertaken until it has

been accepted as meeting the requirements regarding biological and chemical hazards as outlined in Health Canada's Laboratory Biosafety Guidelines. All investigations involving human subjects must be endorsed by the grantee institution's ethics committee and must conform to the guidelines outlined in the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans and/or Human Pluripotent Stem Cell Research: Guidelines for CIHR-Funded Research. Under no circumstances will the Foundation fund research that involves human embryos that are created solely for research purposes or the derivation of stem cells from cloned human embryos that are created solely for research purposes.

Subject to the limitation of its obligations contained in the Agreement, the Foundation agrees to reimburse the grantee institution for the cost of the research project pursuant to which this Award pertains, as specified in the approved budget. The Principal Investigator must submit the expenses to the grantee institution, which will then be submitted to the Foundation for reimbursement. The grantee institution must provide annual reports to the Foundation in accordance with Section 4 of the Agreement for expenditures submitted by the Principal Investigator by August 1st of each year for the duration of the Award. The Foundation reserves the right to withhold funds from subsequent funding years if, in its sole discretion and based on the grantee institution's annual financial report, the budget is significantly underspent. In this event, the Foundation will notify the grantee institution of the termination date for the account. The Foundation will not cover costs incurred prior to the start date or after the termination date of the Award without prior written approval. Subsequent to the termination date of the Award, any unspent funds held at the institution are to be returned to the Foundation.

The grantee institution must advise the Foundation of any commercial activities undertaken by the Principal Investigator that are relevant to the research being funded.

The grantee institution must advise the Foundation of any investigations regarding the actual or alleged misconduct on the part of the Principal Investigator, and the outcome of any such investigation that is relevant to the research being funded under this Agreement.

By signing below the grantee institution agrees to be bound by all of the foregoing terms.

Dr. Mansoor Husain

Name of Director/Associate/VP, VP or Dean,
Research Service

University Health Network

Name of Institution



Signature

April 19, 2013

Date

University Health Network

Toronto General Hospital Toronto Western Hospital Princess Margaret Hospital



This Biosafety Certificate has been issued to the Principal Investigator identified below by the Research Biosafety Officer to authorize the research projects involving biohazards material. All work conducted by UHN Researchers with Biological Agents on UHN premises or under the control of UHN, is to be performed in accordance with the standards of the UHN Research Biosafety Manual.

Principal Investigator: Dr. Gary Levy Telephone #: 416-340-4800 Ext.: 5166

Approval Date: Aug 05, 2011

Certificate Expiry Date: Aug 05, 2013

Project Number: 21016

Project Title: The role of fibrinogen like protein 2 (FGL2) in immunology and developmental biology.

Project Location: Max Bell Research Centre, 2-416

Physical Containment: Level 2

Operational Containment: Level 2

Project Location: Max Bell Research Centre, 2-413

Physical Containment: Level 2

Operational Containment: Level 2

Project Location: Toronto Medical Discovery Tower, 2-601

Physical Containment: Level 1

Operational Containment: Level 1

Project Location: Toronto Medical Discovery Tower, 2-602

Physical Containment: Level 1

Operational Containment: Level 1

Project Location: Toronto Medical Discovery Tower, 2-603

Physical Containment: Level 1

Operational Containment: Level 1

Project Location: Toronto Medical Discovery Tower, 2-605

Physical Containment: Level 2

Operational Containment: Level 2

Project Location: Toronto Medical Discovery Tower, 2-606

Physical Containment: Level 2

Operational Containment: Level 2

Project Location: Toronto Medical Discovery Tower, 2-607

Physical Containment: Level 2

Operational Containment: Level 2

Project Location: Toronto Medical Discovery Tower, 2-608

Physical Containment: Level 2

Operational Containment: Level 2

Project Location: Toronto Medical Discovery Tower, 2-609

Physical Containment: Level 2

Operational Containment: Level 2

University Health Network

Toronto General Hospital Toronto Western Hospital Princess Margaret Hospital

Project Location: Max Bell Research Centre, 2-406

Physical Containment: Level 2 **Operational Containment:** Level 2

Project Location: Toronto Medical Discovery Tower, 6-707

Physical Containment: Level 2 **Operational Containment:** Level 2

Project Location: Toronto Medical Discovery Tower, 2-604

Physical Containment: Level 2 **Operational Containment:** Level 2

Project Location: Toronto Medical Discovery Tower, 2-504

Physical Containment: Level 2 **Operational Containment:** Level 2

Project Location: Toronto Medical Discovery Tower, 4-204

Physical Containment: Level 1 **Operational Containment:** Level 1

Project Location: Toronto Medical Discovery Tower, 2-203

Physical Containment: Level 2 **Operational Containment:** Level 2

Name of the Biological Agent: Animal blood and blood fractions

Common Name: Animal blood

Genus: Mus **Species:** musculus **Strain:**

Name of the Biological Agent: Primary animal tissues or cells

Common Name: Animal tissue and cells

Genus: Mus **Species:** musculus **Strain:**

Name of the Biological Agent: Immortalized animal-cell lines

Common Name: CHO-K1

Genus: Cricetulus **Species:** griseus **Strain:** ATCC CCL-61

Name of the Biological Agent: Other, please specify

Common Name: pIRES selection vector

Genus: pIRES **Species:** from Clontech **Strain:** cat # 631621

Name of the Biological Agent: Immortalized animal-cell lines

Common Name: COS-7 cells

Genus: Cercopithecus **Species:** aethiops **Strain:** ATCC CRL-1651

Name of the Biological Agent: Immortalized animal-cell lines

Common Name: CHO-S

Genus: cricetulus **Species:** griseus **Strain:** Invitrogen 11619-012



Name of the Biological Agent: Human blood and blood fractions

Common Name: human blood

Genus: Homo **Species:** sapiens **Strain:**

University Health Network

Toronto General Hospital Toronto Western Hospital Princess Margaret Hospital

UHN Research Biosafety Officer Approval: 
 Dr. Jeffrey A. Medin